Use of lefamulin in mycobacterium intracellulare infections

CN119700991BActive Publication Date: 2025-10-17BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411973181.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-12-30
Publication Date
2025-10-17
Estimated Expiration
2044-12-30

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The application belongs to the technical field of biological medicine, and particularly relates to application of a semi-synthetic truncated pleuromutilin drug in resisting mycobacterium intracellulare infection. Lefamulin in the application has good bacteriostatic activity on mycobacterium intracellulare standard strains and clinical isolates, and the MIC of the Lefamulin on the mycobacterium intracellulare standard strains can reach 0.25 mu g / mL, and the MIC of the Lefamulin on the mycobacterium intracellulare clinical isolates can reach 0.03125 mu g / mL at best. The application widens the application field of the Lefamulin, and provides a new method for treating mycobacterium intracellulare infection.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Application of Lefamulin in mycobacterium avium complex infection

    CN118416042A

  • Bacteriocin for applications against mycobacterium

    WO2023041435A1